PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Certolizumab pegol - Ankylosing spondylitis
PAD Profile : Certolizumab pegol - Ankylosing spondylitis
Keywords :
Biologic, anti-TNF, TNF-alpha, monoclonal antibody, cytokine modulator, Axial Spondyloarthritis, AS
Brand Names Include :
Cimzia
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
- Any paediatric use
- Rheumatoid arthritis
- Psoriatic arthritis
- Non-radiographic axial spondyloarthritis
- Psoriasis
Additional Documents
Type
Document
Review Date
NICE Technology Appraisal
NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non radiographic axial spondyloarth
Committee Recommendations
Date
Committee Name
Narrative
06 December 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.
Treatment pathway is available on separate guidelines page.
06 July 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN agreed the attached Spondyloarthritis biologic treatment pathway in line with TA383 which was published by NICE in February 2016
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs